AFFIMED NV (AFMD) Stock Fundamental Analysis

NASDAQ:AFMD • NL0015001ZQ0

0.1815 USD
-0.1 (-34.95%)
At close: May 19, 2025
0.1731 USD
-0.01 (-4.63%)
After Hours: 5/19/2025, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AFMD. AFMD was compared to 521 industry peers in the Biotechnology industry. AFMD may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AFMD is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • AFMD had negative earnings in the past year.
  • AFMD had a negative operating cash flow in the past year.
  • In the past 5 years AFMD always reported negative net income.
  • AFMD had a negative operating cash flow in each of the past 5 years.
AFMD Yearly Net Income VS EBIT VS OCF VS FCFAFMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

  • AFMD's Return On Assets of -175.10% is on the low side compared to the rest of the industry. AFMD is outperformed by 87.32% of its industry peers.
  • AFMD has a Return On Equity of -406.92%. This is in the lower half of the industry: AFMD underperforms 75.89% of its industry peers.
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROIC N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
AFMD Yearly ROA, ROE, ROICAFMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

  • AFMD has a Gross Margin of 789.74%. This is amongst the best in the industry. AFMD outperforms 100.00% of its industry peers.
  • In the last couple of years the Gross Margin of AFMD has declined.
  • AFMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 789.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
AFMD Yearly Profit, Operating, Gross MarginsAFMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AFMD remains at a similar level compared to 1 year ago.
  • The debt/assets ratio for AFMD is higher compared to a year ago.
AFMD Yearly Shares OutstandingAFMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
AFMD Yearly Total Debt VS Total AssetsAFMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

  • AFMD has an Altman-Z score of -4.35. This is a bad value and indicates that AFMD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -4.35, AFMD is in line with its industry, outperforming 44.64% of the companies in the same industry.
  • AFMD has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
  • AFMD has a Debt to Equity ratio of 0.35. This is in the lower half of the industry: AFMD underperforms 73.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z -4.35
ROIC/WACCN/A
WACC6.81%
AFMD Yearly LT Debt VS Equity VS FCFAFMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • AFMD has a Current Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.93, AFMD is doing worse than 76.79% of the companies in the same industry.
  • A Quick Ratio of 1.93 indicates that AFMD should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.93, AFMD is not doing good in the industry: 75.36% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
AFMD Yearly Current Assets VS Current LiabilitesAFMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • AFMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.15%, which is quite impressive.
  • AFMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.39%.
  • Measured over the past years, AFMD shows a very negative growth in Revenue. The Revenue has been decreasing by -19.00% on average per year.
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.18% on average over the next years. This is quite good.
  • AFMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.57% yearly.
EPS Next Y40.97%
EPS Next 2Y28.77%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AFMD Yearly Revenue VS EstimatesAFMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
AFMD Yearly EPS VS EstimatesAFMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AFMD. In the last year negative earnings were reported.
  • Also next year AFMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AFMD Price Earnings VS Forward Price EarningsAFMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFMD Per share dataAFMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

  • AFMD's earnings are expected to grow with 19.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.77%
EPS Next 3Y19.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AFMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AFFIMED NV

NASDAQ:AFMD (5/19/2025, 8:00:00 PM)

After market: 0.1731 -0.01 (-4.63%)

0.1815

-0.1 (-34.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02
Earnings (Next)06-09
Inst Owners22.64%
Inst Owner Change-98.95%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap2.76M
Revenue(TTM)877.00K
Net Income(TTM)-69.97M
Analysts84
Price Target12.24 (6643.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.56%
Min EPS beat(2)-10.88%
Max EPS beat(2)1.75%
EPS beat(4)3
Avg EPS beat(4)4.52%
Min EPS beat(4)-10.88%
Max EPS beat(4)14.22%
EPS beat(8)4
Avg EPS beat(8)1.65%
EPS beat(12)7
Avg EPS beat(12)6.57%
EPS beat(16)8
Avg EPS beat(16)-11.38%
Revenue beat(2)0
Avg Revenue beat(2)-90.72%
Min Revenue beat(2)-92.4%
Max Revenue beat(2)-89.04%
Revenue beat(4)0
Avg Revenue beat(4)-85.87%
Min Revenue beat(4)-92.4%
Max Revenue beat(4)-74.24%
Revenue beat(8)2
Avg Revenue beat(8)-47.19%
Revenue beat(12)4
Avg Revenue beat(12)-23.39%
Revenue beat(16)7
Avg Revenue beat(16)-15.7%
PT rev (1m)0%
PT rev (3m)-11.76%
EPS NQ rev (1m)-5.91%
EPS NQ rev (3m)-5.91%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-83.93%
Revenue NQ rev (3m)-83.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.78
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-5.18
EYN/A
EPS(NY)-2.73
Fwd EYN/A
FCF(TTM)-5.77
FCFYN/A
OCF(TTM)-5.73
OCFYN/A
SpS0.07
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -175.1%
ROE -406.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 789.74%
FCFM N/A
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 60.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -4.35
F-Score1
WACC6.81%
ROIC/WACCN/A
Cap/Depr(3y)175.27%
Cap/Depr(5y)145.6%
Cap/Sales(3y)18.76%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
EPS Next Y40.97%
EPS Next 2Y28.77%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%
EBIT growth 1Y42.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.28%
OCF growth 3YN/A
OCF growth 5YN/A

AFFIMED NV / AFMD FAQ

What is the fundamental rating for AFMD stock?

ChartMill assigns a fundamental rating of 2 / 10 to AFMD.


What is the valuation status of AFFIMED NV (AFMD) stock?

ChartMill assigns a valuation rating of 0 / 10 to AFFIMED NV (AFMD). This can be considered as Overvalued.


What is the profitability of AFMD stock?

AFFIMED NV (AFMD) has a profitability rating of 1 / 10.


What is the earnings growth outlook for AFFIMED NV?

The Earnings per Share (EPS) of AFFIMED NV (AFMD) is expected to grow by 40.97% in the next year.